Efficacy of tolvaptan in patients with refractory ascites in a clinical setting

doi:10.4254/wjh.v7.i12.1685

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6800)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-6) series.

Item

Count

PDF

517

WORD

273

HTML

3038

Figures (1-6)

127

Tables (1-6)

125

Sum=4080

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1284

Download

1436

Sum=2720

Jun 28, 2015 (publication date) through May 17, 2024

Times Cited of This Article

Times Cited (21)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Jun 28, 2015; 7(12): 1685-1693
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1685

Full Size Figure Download Figure

Figure 5 The cumulative incidence rate was significantly higher in the control group, with a median incidence time of 30 d in the tolvaptan group and 20 d in the control group.

Citation: Ohki T, Sato K, Yamada T, Yamagami M, Ito D, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K. Efficacy of tolvaptan in patients with refractory ascites in a clinical setting. World J Hepatol 2015; 7(12): 1685-1693
URL: https://www.wjgnet.com/1948-5182/full/v7/i12/1685.htm
DOI: https://dx.doi.org/10.4254/wjh.v7.i12.1685